X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NATCO PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NATCO PHARMA DISHMAN PHARMA/
NATCO PHARMA
 
P/E (TTM) x 25.1 24.3 103.4% View Chart
P/BV x 3.3 18.4 18.2% View Chart
Dividend Yield % 0.7 0.6 106.7%  

Financials

 DISHMAN PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NATCO PHARMA
Mar-14
DISHMAN PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs374877 42.7%   
Low Rs129424 30.4%   
Sales per share (Unadj.) Rs197.8223.4 88.5%  
Earnings per share (Unadj.) Rs21.231.1 68.3%  
Cash flow per share (Unadj.) Rs34.740.3 86.2%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.80.8 103.4%  
Book value per share (Unadj.) Rs179.9219.5 82.0%  
Shares outstanding (eoy) m80.6933.07 244.0%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x1.32.9 43.7%   
Avg P/E ratio x11.920.9 56.7%  
P/CF ratio (eoy) x7.216.1 44.9%  
Price / Book Value ratio x1.43.0 47.2%  
Dividend payout %9.416.1 58.6%   
Avg Mkt Cap Rs m20,30621,504 94.4%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3551,128 474.9%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,9617,389 216.0%  
Other income Rs m265167 158.8%   
Total revenues Rs m16,2267,556 214.7%   
Gross profit Rs m4,1031,793 228.8%  
Depreciation Rs m1,091304 358.3%   
Interest Rs m944366 257.9%   
Profit before tax Rs m2,3341,290 180.9%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624309 202.0%   
Profit after tax Rs m1,7111,027 166.5%  
Gross profit margin %25.724.3 105.9%  
Effective tax rate %26.723.9 111.7%   
Net profit margin %10.713.9 77.1%  
BALANCE SHEET DATA
Current assets Rs m11,0183,681 299.3%   
Current liabilities Rs m9,5173,123 304.8%   
Net working cap to sales %9.47.6 124.4%  
Current ratio x1.21.2 98.2%  
Inventory Days Days11089 123.5%  
Debtors Days Days3559 59.4%  
Net fixed assets Rs m16,3047,685 212.1%   
Share capital Rs m161331 48.8%   
"Free" reserves Rs m12,9076,670 193.5%   
Net worth Rs m14,5167,259 200.0%   
Long term debt Rs m4,189955 438.7%   
Total assets Rs m29,80511,957 249.3%  
Interest coverage x3.54.5 76.8%   
Debt to equity ratio x0.30.1 219.4%  
Sales to assets ratio x0.50.6 86.7%   
Return on assets %8.911.7 76.4%  
Return on equity %11.814.2 83.3%  
Return on capital %17.520.7 84.6%  
Exports to sales %24.839.4 63.0%   
Imports to sales %3.75.7 65.5%   
Exports (fob) Rs m3,9562,908 136.1%   
Imports (cif) Rs m596421 141.6%   
Fx inflow Rs m4,9523,445 143.7%   
Fx outflow Rs m697703 99.1%   
Net fx Rs m4,2552,743 155.1%   
CASH FLOW
From Operations Rs m2,7861,440 193.5%  
From Investments Rs m-1,529-1,089 140.4%  
From Financial Activity Rs m-941-353 266.8%  
Net Cashflow Rs m316-1 -21,234.9%  

Share Holding

Indian Promoters % 61.4 52.0 118.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 3.7 7.8 47.2%  
FIIs % 12.7 16.6 76.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 26.0 85.0%  
Shareholders   46,261 25,395 182.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS